Every day, doctors across various specialties diagnose cases of inflammatory arthritis, enteropathy, hyperinsulinemic ...

Vir Biotechnology (NASDAQ:VIR) on Friday announced 24-week post-end-of-treatment data from a mid-stage trial for tobevibart ...

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

Richard Lepke; Senior Director, Investor Relations; Vir Biotechnology Inc. Marianne De Backer; Chief Executive Officer, Director; Vir Biotechnology Inc. Mark Eisner; ...

Get insights into Vir Biotechnology's Q1 2025 earnings call, including ECLIPSE Phase III trial progress, oncology updates, and financial highlights.

Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of ...

Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2025.

Results from the Phase III MYR301 trial show that 36% of patients who achieved undetectable hepatitis delta virus levels when ...

Hundreds of Delta passengers experienced significant delays on Thursday night after two international flights were diverted to Montgomery, Alabama, due to severe weather. Flying to Atlanta ...

LONDON, UK / ACCESS Newswire / May 6, 2025 / A new report released today by the World Hepatitis Alliance (WHA) reveals widespread knowledge gaps, inequities in access, and critical systemic barriers i ...

A new report released today by the World Hepatitis Alliance (WHA) reveals widespread knowledge gaps, inequities in access, ...

Assembly Biosciences, Inc.’s ASMB share price has dipped by 5.02%, which has investors questioning if this is right time to ...